Drug news
RTS,S anti malaria vaccine success in large African study
RTS,S, a new experimental vaccine from GlaxoSmithKline, with research funded in part through grants from the Bill & Melinda Gates Foundation, has been shown in interim Phase III results to significantly reduce the incidence of both clinical and severe malaria in African children. In a study of 15 410 children in Africa RTS, S RTS,S reduced the incidence of clinical malaria by 55.8% following vaccination with all three doses compared to a subject group inoculated with a non-malaria vaccine.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins